- Home
- NCNA vs GLTO Comparison
NCNA vs GLTO Comparison
Compare NCNA & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCNA
- GLTO
- Stock Information
- Founded
- NCNA 1997
- GLTO 2011
- Country
- NCNA United Kingdom
- GLTO Denmark
- Employees
- NCNA N/A
- GLTO N/A
- Industry
- NCNA Biotechnology: Pharmaceutical Preparations
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- NCNA Health Care
- GLTO Health Care
- Exchange
- NCNA Nasdaq
- GLTO Nasdaq
- Market Cap
- NCNA 4.5M
- GLTO 4.5M
- IPO Year
- NCNA 2017
- GLTO 2020
- Fundamental
- Price
- NCNA $0.05
- GLTO $3.54
- Analyst Decision
- NCNA Buy
- GLTO Buy
- Analyst Count
- NCNA 2
- GLTO 1
- Target Price
- NCNA $25.00
- GLTO $10.00
- AVG Volume (30 Days)
- NCNA 208.6M
- GLTO 13.7K
- Earning Date
- NCNA 08-14-2025
- GLTO 08-11-2025
- Dividend Yield
- NCNA N/A
- GLTO N/A
- EPS Growth
- NCNA N/A
- GLTO N/A
- EPS
- NCNA N/A
- GLTO N/A
- Revenue
- NCNA N/A
- GLTO N/A
- Revenue This Year
- NCNA N/A
- GLTO N/A
- Revenue Next Year
- NCNA N/A
- GLTO N/A
- P/E Ratio
- NCNA N/A
- GLTO N/A
- Revenue Growth
- NCNA N/A
- GLTO N/A
- 52 Week Low
- NCNA $0.03
- GLTO $2.01
- 52 Week High
- NCNA $10.79
- GLTO $16.07
- Technical
- Relative Strength Index (RSI)
- NCNA 38.50
- GLTO 59.96
- Support Level
- NCNA $0.05
- GLTO $3.24
- Resistance Level
- NCNA $0.13
- GLTO $3.60
- Average True Range (ATR)
- NCNA 0.02
- GLTO 0.26
- MACD
- NCNA 0.00
- GLTO -0.01
- Stochastic Oscillator
- NCNA 4.62
- GLTO 60.98
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.